|
Millipore
to invest Rs 500 cr in bio-science worldwide
Vijaya
K - Bangalore
Millipore
Bioscience, a division of Millipore (India), which has a joint venture
with Millipore Corporation, USA, an acknowledged world leader in
membrane technology, is planning for an investment of Rs 500 crore
for manufacture and research in bioscience worldwide in the next
two years. To tap the vast potential and to cater to the needs of
the new life science area Millipore has set up its new division
Millipore BioScience comprising of biopharmaceutical, advance micro
biology, life science division and labwater division.
‘‘The
needs of the customers are changing with time. We are looking at
new product materials by which we can provide solutions to the bioscience
segment,’’ says Sudhir Kant, president, Millipore (India).
‘‘Global market in the bioscience segment is huge. The
disease target which was around 500 worldwide will increase to 10,000
in the next ten years and this would create a huge market,’’
he adds.
‘‘We
foresee great potential with companies like Reliance which is investing
Rs 150 crore in first phase for research in biotech sector. Nearly
100 companies are coming in for manufacturing as well as research.
We also have few majors like Wockhardt which plans for Rs 200 crore
investment in this segment in next two years, Cadila Pharma, Shantha
Biotech, Bharat Biotech, Indian Immunologicals, Panacea, Intel,
Ranbaxy, Avastha Zen and Institute of Human Genetics. Around 45
companies are expected to come up in Bangalore either in the area
of bioscience, biotechnology or life science,’’ says Sudhir.
Millipore India is in talks with Shantha Biotech, Bharat Biotech
and Cadila who have invested in bioscience segment.
|
